Itacitinib for GVHD Prevention
Single Center Pilot Study to Investigate the Efficacy of Adding Itacitinib to Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning Matched Donor Hematopoietic Cell Transplantation With Peripheral Blood Stem Cells as Graft Source
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 50 patients (estimated)
- Sponsors
- City of Hope Medical Center
- Collaborators
- National Cancer Institute (NCI)
- Tags
- Allogeneic Stem Cell Transplant, Chemotherapy, JAK1 Inhibitor, Post-Allogeneic Stem Cell Transplant
- Trial Type
- Supportive
- Last Update
- 2 months ago
- SparkCures ID
- 1652
- NCT Identifier
- NCT05364762
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.